Q3 EPS Estimate for Capricor Therapeutics Reduced by Analyst

Key Points

• B. Riley has reduced its earnings estimates for Capricor Therapeutics for Q3 2025, predicting earnings of ($0.47) per share, down from a previous estimate of ($0.46).
• Several research firms have adjusted their ratings and price targets for Capricor, with Cantor Fitzgerald maintaining an "overweight" rating and a $30.00 price target, while Oppenheimer reduced its price target from $43.00 to $22.00.
• Capricor Therapeutics reported a negative earnings miss in its latest quarterly results, with earnings per share at ($0.57), below the consensus estimate of ($0.48).

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - B. Riley reduced their Q3 2025 earnings per share estimates for Capricor Therapeutics in a note issued to investors on Tuesday, August 12th. B. Riley analyst M. El-Saadi now expects that the biotechnology company will earn ($0.47) per share for the quarter, down from their previous estimate of ($0.46). B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.85) EPS and FY2027 earnings at ($0.38) EPS.

Other equities analysts have also recently issued research reports about the stock. Jones Trading dropped their target price on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. Roth Capital reduced their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a research note on Monday, July 14th. HC Wainwright reduced their price target on shares of Capricor Therapeutics from $77.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, July 11th. Cantor Fitzgerald restated an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Finally, Oppenheimer cut their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $22.56.

Capricor Therapeutics Stock Down 0.4%

Capricor Therapeutics stock traded down $0.03 during trading hours on Friday, reaching $7.67. 1,272,397 shares of the company's stock were exchanged, compared to its average volume of 2,015,986. The firm's 50 day simple moving average is $9.06 and its 200 day simple moving average is $10.88. The firm has a market capitalization of $350.65 million, a PE ratio of -4.68 and a beta of 0.59. Capricor Therapeutics has a twelve month low of $3.94 and a twelve month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in shares of Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock worth $67,000 after purchasing an additional 4,976 shares during the period. BNP Paribas Financial Markets raised its position in shares of Capricor Therapeutics by 2,342.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company's stock valued at $361,000 after purchasing an additional 34,908 shares in the last quarter. Jump Financial LLC raised its position in shares of Capricor Therapeutics by 42.6% in the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock valued at $2,309,000 after purchasing an additional 69,515 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $796,000. Finally, Rhumbline Advisers raised its position in shares of Capricor Therapeutics by 7.3% during the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company's stock valued at $531,000 after acquiring an additional 3,636 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.